Northeast Pharmaceutical Group Beheer

Beheer criteriumcontroles 2/4

De CEO Northeast Pharmaceutical Group is Zhou Kai, benoemd in May2019, heeft een ambtstermijn van 5.5 jaar. bezit rechtstreeks 0.3% van de aandelen van het bedrijf, ter waarde CN¥ 21.94M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 5 jaar.

Belangrijke informatie

Zhou Kai

Algemeen directeur

CN¥1.8m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	5.5yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	5yrs

Recente managementupdates

Recent updates

CEO

Zhou Kai (60 yo)

5.5yrs

Tenure

CN¥1,824,100

Compensatie

Mr. Zhou Kai serves as a General Manager of Northeast Pharmaceutical Group Co., Ltd. since May 8, 2019 and serves its Non-Independent Director since November 29, 2020. He served as a Vice President of Nort...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Zhou Kai	GM & Director	5.5yrs	CN¥1.82m	0.30% CN¥ 21.9m
Jialun Song	Financial Director & Secretary	1.8yrs	CN¥2.14m	0.022% CN¥ 1.7m
Xiao Feng	Deputy General Manager	less than a year	CN¥894.30k	geen gegevens
Yonggang Cai	Deputy General Manager	less than a year	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 000597 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Zhou Kai	GM & Director	4yrs	CN¥1.82m	0.30% CN¥ 21.9m
Demin Han	Independent Director	6.3yrs	CN¥150.00k	geen gegevens
Zhaochun Tan	Non-Independent Director	3yrs	geen gegevens	geen gegevens
Chengren Huang	Non-Independent Director	6.3yrs	geen gegevens	0.23% CN¥ 16.7m
Xinhua Ao	Non-Independent Director	6.3yrs	geen gegevens	0.23% CN¥ 16.7m
Guodong Wang	Independent Director	6.3yrs	CN¥150.00k	geen gegevens
Hui Yao	Independent Director	6.3yrs	CN¥150.00k	geen gegevens
Youguang Shang	Independent Director	4.1yrs	CN¥150.00k	geen gegevens
Jianmin Guo	Chairman of the Board	3.1yrs	CN¥2.07m	0.22% CN¥ 16.6m
Zhihua Huang	Non-Independent Director	3yrs	geen gegevens	0.070% CN¥ 5.2m
Baidan Zhan	Chairman of the Supervisory Board	5.9yrs	geen gegevens	geen gegevens
Hai Tian	Director	1.2yrs	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 000597 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Northeast Pharmaceutical Group Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Recent updates

Now 21% undervalued

Investor sentiment improves as stock rises 22%

Third quarter 2024 earnings released: EPS: CN¥0.036 (vs CN¥0.059 in 3Q 2023)

Investor sentiment improves as stock rises 19%

Northeast Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.045 in 2Q 2023)

Investor sentiment deteriorates as stock falls 22%

New minor risk - Share price stability

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Dividend of CN¥0.10 announced

Northeast Pharmaceutical Group Co., Ltd. Implements 2023 Final Cash Profit Distribution Plan, Payable on 23 May 2024

New minor risk - Earnings quality

First quarter 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.049 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in FY 2022)

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment deteriorates as stock falls 18%

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

High number of new directors

Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.033 in 2Q 2022)

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. Announces 2022 Final Cash Profit Distribution Plan, Payable on 16 May 2023

Full year 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.07 in FY 2021)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.026 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.016 in 2Q 2021)

High number of new directors

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Dividend for the Year 2021, Payable on 27 May 2022

First quarter 2022 earnings released: EPS: CN¥0.051 (vs CN¥0.029 in 1Q 2021)

Northeast Pharmaceutical Group Co., Ltd. Approves the Profit Distribution for 2021

Full year 2021 earnings released: EPS: CN¥0.07 (vs CN¥0.01 in FY 2020)

Northeast Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for 2021

High number of new directors

Third quarter 2021 earnings released: CN¥0.026 loss per share (vs CN¥0.042 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.016 (vs CN¥0.063 in 2Q 2020)

Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend of A Shares, Payable on 27 May 2021

First quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.013 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.01 (vs CN¥0.13 in FY 2019)

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2020

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 17, 2021

New 90-day low: CN¥4.86

New 90-day low: CN¥5.03

New 90-day low: CN¥5.37

New 90-day low: CN¥5.39

Third quarter earnings released

Northeast Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Jiangxi Fangda Steel Technology Co., Ltd. completed the acquisition of an additional 10% stake in Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) for approximately CNY 890 million.

Northeast Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 2 billion in funding from Joyvio Group Co., Ltd., Liaoning Fangda Group Industrial Co., Ltd., and other investors

First half earnings released

New 90-day high - CN¥6.15

New 90-day high - CN¥6.02

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd